

Table S1. Categories of concomitant medications administered to dogs with mast cell tumors receiving vinblastine compared to toceranib.

Category	Toceranib		Vinblastine	
	# Dogs Treated (%)	# Times Rx'ed	# Dogs Treated (%)	# Times Rx'ed
Anti-nausea	16 (27)	20	6 (21)	7
Anti-diarrhea	29 (48)	32	9 (32)	10
Antibiotics	19 (32)	31	12 (43)	12
Cardiac/BP	5 (8)	9	1 (4)	3
Ocular	2 (3)	4	1 (4)	6
Pain	21 (35)	25	8 (29)	11
Supplements	7 (12)	12	2 (7)	3
Miscellaneous	23 (38)	35	7 (25)	10
None	10 (17)		5 (18)	

Legend: BP, blood pressure.

Medications included in each category are as follows: 1) Anti-nausea: maropitant, ondansetron, metoclopramide, bismuth subsalicylate; 2) Anti-diarrhea: metronidazole, tylosin, loperamide; 3) Antibiotics: enrofloxacin, trimethoprim sulfa, cephalexin, Clavamox, amoxicillin, Simplicef, Convenia, cefazolin, clindamycin, Unasyn, ampicillin, minocycline; 4) Cardiac/BP: enalapril, amlodipine, atenolol, aspirin; 5) Ocular: prednisolone acetate 0.1% ophthalmic, cyclosporine ophthalmic 2%, Diclofenac, tobramycin ophthalmic, Genteal, Sochlor 5% ointment, terramycin, Vigamox solution, gentamicin ophthalmic; 6) Pain: tramadol, gabapentin, amantadine, carprofen, hydromorphone, lidocaine, Tylenol 3; 7) Supplements: glucosamine, Denamarin, fish oil,

Cosequin; 9) Miscellaneous: variety of medications to treat otic infections, urinary incontinence, hypothyroidism, and skin conditions, as well as other gastrointestinal medications, etc.

Table S2. Characteristics of disease progression in dogs being treated with toceranib or vinblastine.

	Toceranib (n=54)	Vinblastine (n=27)
Local only	15 (28%)	7 (26%)
<i>De novo</i> only	2 (4%)	1 (4%)
Metastasis to lymph node	1 (2%)	1 (4%)
Local + <i>de novo</i>	3 (6%)	3 (11%)
Metastasis to spleen		1 (4%)
Progressive lymph node	1 (2%)	
Metastasis to spleen + liver	1 (2%)	
Local + progressive lymph node		1 (4%)